EGFR and neoplasm: The results of a meta-analysis of 15 studies involving 2471 patients with ovarian cancer for the EGFR expression found positive EGFR immunostaining in 6.2% to 72.6% (median 35%) of tumours, and in 7 studies (63.6%) EGFR expression was found to be predictive of a poorer overall survival [60].